Bisphosphonate nephropathy: A case series and review of the literature

Camiel de Roij van Zuijdewijn*, Wim van Dorp, Sandrine Florquin, Joris Roelofs, Kees Verburgh

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

From rat studies, human case reports and cohort studies, bisphosphonates seem to impair renal function. However, when critically reviewing the literature, zoledronate and pamidronate are more frequently involved in renal deterioration than other bisphosphonates. When bisphosphonate nephropathy occurs, zoledronate more frequently induces tubular toxicity whereas pamidronate typically induces focal segmental glomerulosclerosis. Thus, although bisphosphonates are highly effective in preventing complications for patients with osseous metastases and are highly effective in preventing fractures for patients with osteoporosis, renal function should be monitored closely after initiation of these drugs.
Original languageEnglish
JournalBritish Journal of Clinical Pharmacology
Early online date2021
DOIs
Publication statusE-pub ahead of print - 2021

Cite this